These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19875732)

  • 1. Optimizing antiplatelet therapy in high-risk patients with atrial fibrillation: insights from Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE A).
    Seet RC; Chen CP
    Stroke; 2009 Dec; 40(12):3883-5. PubMed ID: 19875732
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
    Meinertz T
    Internist (Berl); 2007 Aug; 48(8):874-5. PubMed ID: 17628764
    [No Abstract]   [Full Text] [Related]  

  • 3. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
    Healey JS; Hart RG; Pogue J; Pfeffer MA; Hohnloser SH; De Caterina R; Flaker G; Yusuf S; Connolly SJ
    Stroke; 2008 May; 39(5):1482-6. PubMed ID: 18323500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    ; Connolly S; Pogue J; Hart R; Pfeffer M; Hohnloser S; Chrolavicius S; Pfeffer M; Hohnloser S; Yusuf S
    Lancet; 2006 Jun; 367(9526):1903-12. PubMed ID: 16765759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation: the ACTIVE W trial.
    DeSilvey DL
    Am J Geriatr Cardiol; 2006; 15(5):326-7. PubMed ID: 16957455
    [No Abstract]   [Full Text] [Related]  

  • 6. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.
    ; ; Connolly S; Yusuf S; Budaj A; Camm J; Chrolavicius S; Commerford PJ; Flather M; Fox KA; Hart R; Hohnloser S; Joyner C; Pfeffer M; Anand I; Arthur H; Avezum A; Bethala-Sithya M; Blumenthal M; Ceremuzynski L; De Caterina R; Diaz R; Flaker G; Frangin G; Franzosi MG; Gaudin C; Golitsyn S; Goldhaber S; Granger C; Halon D; Hermosillo A; Hunt D; Jansky P; Karatzas N; Keltai M; Lanas F; Lau CP; Le Heuzey JY; Lewis BS; Morais J; Morillo C; Oto A; Paolasso E; Peters RJ; Pfisterer M; Piegas L; Pipillis T; Proste C; Sitkei E; Swedberg K; Synhorst D; Talajic M; Trégou V; Valentin V; van Mieghem W; Weintraub W; Varigos J
    Am Heart J; 2006 Jun; 151(6):1187-93. PubMed ID: 16781218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
    Connolly SJ; Eikelboom JW; Ng J; Hirsh J; Yusuf S; Pogue J; de Caterina R; Hohnloser S; Hart RG;
    Ann Intern Med; 2011 Nov; 155(9):579-86. PubMed ID: 22041946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New antiaggregants and their importance for the practitioner].
    Tsakiris DA
    Ther Umsch; 2003 Jan; 60(1):24-6. PubMed ID: 12638474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrial fibrillation, is warfarin the only option for stroke prevention?
    Khan M; Kamal AK
    J Pak Med Assoc; 2011 Mar; 61(3):301-2. PubMed ID: 21465955
    [No Abstract]   [Full Text] [Related]  

  • 10. Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
    De Caterina R; Connolly SJ; Pogue J; Chrolavicius S; Budaj A; Morais J; Renda G; Yusuf S;
    Eur Heart J; 2010 Sep; 31(17):2133-40. PubMed ID: 20685676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
    Lopes RD; Li L; Granger CB; Wang TY; Foody JM; Funk M; Peterson ED; Alexander KP
    Am J Med; 2012 Sep; 125(9):897-905. PubMed ID: 22795814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
    Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel hydrogen sulphate for atrial fibrillation.
    Garg N; Rajpurohit N; Flaker G
    Expert Opin Pharmacother; 2011 Aug; 12(11):1781-7. PubMed ID: 21663525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
    Wang TH; Bhatt DL; Fox KA; Steinhubl SR; Brennan DM; Hacke W; Mak KH; Pearson TA; Boden WE; Steg PG; Flather MD; Montalescot G; Topol EJ;
    Eur Heart J; 2007 Sep; 28(18):2200-7. PubMed ID: 17673448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
    Prescrire Int; 2009 Dec; 18(104):272-3. PubMed ID: 20027714
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
    Spinler SA
    Pharmacotherapy; 2009 Jul; 29(7):812-21. PubMed ID: 19558255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel and [symbol: see text] ticlopidine--improvements on aspirin?
    Drug Ther Bull; 1999 Aug; 37(8):59-61. PubMed ID: 10696686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
    J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery.
    Cannon CP; Mehta SR; Aranki SF
    Ann Thorac Surg; 2005 Aug; 80(2):768-79. PubMed ID: 16039260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.